Anwaar Saeed
@AnwaarSaeed3
Followers
3K
Following
3K
Media
112
Statuses
1K
Associate Professor & Chief of Gastrointestinal Oncology @PittTweet @UPMCnews @UPMCHillmanCC
Pittsburgh, PA
Joined March 2019
🙏🏻 @NatureComms for being the 🏡 to our foundational work 😇✨✨ 🙏🏻 my fearless team of investigators for the Elite teamwork ⛷️⛷️⛷️ >>>> watch out for our follow up paper with deeper molecular dive & AI work 😎 https://t.co/piwERqbAVb
🔥off the press: clinical & biomarker results of CAMILLA CRC cohort, positive outcome w differential advantage in RAS wild-type population. Insightful spatial transcriptomic findings laying the foundation for ongoing phase III STELLAR 303 trial ✨@UPMCHillmanCC @OncoAlert
6
18
93
Exercise as anti-cancer medicine (“Exercizumab”) @Cancer_Cell
https://t.co/51bb4qGQfY
@JCO_ASCO
https://t.co/tBcD44WuML
4
121
425
A wonderful 3rd Annual Pittsburgh GI Cancer Summit. Deeply grateful to our sponsors and to all of our exceptional speakers for making it a success. 😇 @CathyEngMD @KimmieNgMD @smitha42 @PancPathologist @MaenAbdelrahim @DennisJHsu @JanieYZhang @JohnRheeMD @UPMCHillmanCC
4
5
26
Congratulations to @AnwaarSaeed3 and the organizing committee for another successful GI oncology Summit. Great discussions with esteemed speakers on 🔥 topics of GI cancers!!
0
1
8
What am I Thankful for this Thanksgiving ? All the therapeutic breakthroughs discussed at The Pittsburgh GI Cancer Summit @UPMCHillmanCC @AnwaarSaeed3 @CathyEngMD @smitha42 @KimmieNgMD
0
4
10
Dr. @smitha42 @FightCRC Research #ASCO25 updates discussed DSP107, a first-in-class bi-specific 4-1BB T-cell engager, w/ & w/o atezolizumab in MSS mCRC pts NOW: Phase 2b trial to open 10 US/Australian sites NCT07235293 PI: @AnwaarSaeed3 at 35 minutes https://t.co/Q918WPoMuT
0
2
4
Thank you to everyone who joined us for the 9th Annual Advances in #ColorectalOncology Symposium @MSKCancerCenter. Each year, this program serves as a vital forum for exchanging insights and exploring the latest evidence-based and multidisciplinary approaches to treating
0
6
12
Now is your last chance to register for the Pittsburgh Third Annual GI Cancer Summit! We will soon be gathering to discuss the latest research and insights. If you are thinking of making last-minute plans, be sure to register via the link below.
1
2
1
📺 Watch our new roundtable series featuring Drs. Zev Wainberg, @AnwaarSaeed3, @MDmanishshah, and @rutikamehtaMD in a discussion on the growing treatment landscape of upper #gastrointestinal cancers, focusing on perioperative immunotherapy and more:
0
1
3
my full #HealthcareUnfiltered EXPRESS podcast with @AnwaarSaeed3 on her recent publication at @TheLancet is here - The paper addresses refractory colorectal cancer (STELLAR-303) trial. Anwaar puts the data in context of current treatment landscape. https://t.co/s2r5JHPGU4
0
2
6
On a new #HealthcareUnfiltered EXPRESS, I am joined by @AnwaarSaeed3 of @UPMC to share the data she presented at @myESMO #ESMO25, which was then published in @TheLancet - learn about the data and background behind this global study as Anwaar puts it in context.
0
1
4
Its a pleasure to announce that our latest article on application of CAR-T therapy in HCC has been published in the prestigious journal of Cancer Treatment Reviews (IF 10.5) Special thanks to my wonderful mentor @AnwaarSaeed3 and @doctoralamiy 😍🙏 @UPMCnews @UPMCHillmanCC
0
1
10
Enjoyed presenting STELLAR-303 results at the 9th Annual @MSKCancerCenter Symposium on Advances in Colorectal Oncology. Inspiring discussions with world-class colleagues pushing the boundaries of #CRC research. @OncoAlert @UPMCHillmanCC
1
3
24
Zanzalintinib + atezolizumab extended OS to 10.9 mo vs 9.4 mo with regorafenib in previously treated mCRC (HR = 0.80; P = .0045) 🌍 Benefit consistent across key subgroups. Full #ESMO25 data ➡️
onclive.com
Zanzalintinib plus atezolizumab demonstrate potential chemotherapy-free option in previously treated metastatic CRC.
0
2
6
@RyanSweeneyMD @TumorBoardTues @AnwaarSaeed3 @IntegrityCE @myESMO @TheLancet #tumorboardtuesday 🧐I don't know about you all - but I now feel fully prepared and confident in offering a patient zanza + atezo (assuming the combination gets approved) 🙏Thank you @AnwaarSaeed3 and @RyanSweeneyMD. That was a highly instructive session
1
3
5
@TumorBoardTues @AnwaarSaeed3 @IntegrityCE @myESMO 11/29 #TumorBoardTuesday Zanzalintinib – Multi-TKI (VEGFR, MET, TAM) demonstrates antitumor activity in preclinical and early-phase human studies When combined with ICI ➡️ TME remodeling ➡️ improved efficacy of ICI Figure courtesy of @AnwaarSaeed3 🔗⬇️ https://t.co/J4xSvbKaYi
2
3
5
@TumorBoardTues @AnwaarSaeed3 @IntegrityCE @myESMO 5/29 #TumorBoardTuesday Mini Tweetorial #1 👨🏫 MSS #CRC is “immune cold” with low TMB, low rates of neoantigens, and a unique tumor microenvironment with scarce tumor-infiltrating lymphocytes Review article 🔗⬇️ https://t.co/oPYHJHv2Kf
evidence.nejm.org
Colorectal cancer treatment has evolved considerably in the last decade with the development of immunotherapies. Immune checkpoint inhibitor therapies have brisk and durable responses in patients w...
1
3
6
4 GI Malignancy studies that we touched on with @rachnatshroff for #ESMO25: ✅ #DYNAMICIII ✅ #STELLAR303 ✅ #MATTERHORN ✅ #FORTITUDE101
#OncTwitter #MedTwitter @OncUpdates @myESMO @OncoAlert #gism
GI Malignancies Highlights from #ESMO25 with @rachnatshroff! ✅ #DYNAMICIII & #PEGASUS ✅ #STELLAR303 ✅ #MATTERHORN ✅ #FORTITUDE101 Full Discussion: - https://t.co/7tZQJM2KWc - Also on “Oncology Brothers” podcast #OncTwitter #gism @myESMO @OncUpdates
0
42
97
#TumorBoardTuesday 💙Did I hear that there was a ➕ Ph3 trial in met #colorectalcancer ⁉️ 📢Join us Tuesday, 11-04-25 at 8PM ET as @AnwaarSaeed3 & @RyanSweeneyMD🗣️Stellar 303 and the emerging Role for IO regimens in MSS/pMMR CRC✅ RT and bring others into the discussion‼️
2
7
18